Timeline | Returns | Volume |
---|---|---|
Daily | -1.89% | 9,83,348 |
Weekly | 1.59% | 45,05,536 |
Monthly | 11.24% | 2,88,90,722 |
Timeline | Daily | Weekly | Monthly |
---|---|---|---|
ALEMBICLTD | -1.89% | 1.59% | 11.24% |
Index | - | - | - |
Peer Avg. | 1.14% | 4.06% | 11.33% |
Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
---|---|---|---|---|---|---|
ALEMBICLTD | 15.02 | 1.29 | 20.46 | 6.45 | 7.35 | 2.53 |
Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
Peer Avg. | 38.60 | 4.35 | 13.48 | 12.96 | 16.49 | 0.78 |
Metrics | Sales Growth | Profit Growth | ROE | ROCE |
---|---|---|---|---|
FY '21-22 | 5.74% | 532.06% | 6.45% | 7.35% |
FY '20-21 | -1.22% | -85.42% | 1.39% | 1.75% |
FY '19-20 | -40.39% | 127.02% | 13.99% | 14.05% |
Metrics | Sales | Expenditure | EBITDA | PAT |
---|---|---|---|---|
FY '21-22 | 77.10 | 63.67 | 102.56 | 85.95 |
FY '20-21 | 72.91 | 62.65 | 21.02 | 13.60 |
FY '19-20 | 73.81 | 70.45 | 96.93 | 93.29 |
Metrics | Sales | Expenditure | EBITDA | PAT |
---|---|---|---|---|
ALEMBICLTD | 77.10 | 63.67 | 102.56 | 85.95 |
SOLARA | 1,268.34 | 1,188.18 | 99.55 | -58.42 |
IOLCP | 2,184.02 | 1,926.73 | 289.32 | 166.66 |
Alembic Limited is an Indian company that develops, manufactures and markets pharmaceutical products such as dosage forms and active ingredients. The company operates through one segment, Pharmaceuticals. The Pharmaceutical segment manufactures and markets fermentation and chemical-based active ingredients (API). The company also conducts R&D in Vadodara. The company manufactures/provides three main products/services: Azithromycin, Venlafaxine and Telmisartan.